HC Wainwright & Co. Reiterates Buy on Uranium Energy, Maintains $8.25 Price Target

Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?

Cryoport Inc.

provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. By offering a platform of end-to-end, fast and technologically advanced packaging and logistics services, Cryoport has filled a key need supporting cell and gene therapies.

In the biotech industry, the cell and gene therapy (CGT) market in particular has seen significant growth and has ample room to expand further given longer life expectancies and increasing demand for personalized medicine. Currently worth $18.61 billion, it has been forecasted by Precedence Research to grow at a compound annual growth rate (CAGR) of 22.41% to over $93 billion by 2030. This is in response to massive investment and innovation in the market that has seen 20 Food and Drug Administration […]

Click here to view original web page at www.benzinga.com

About the author: StockMan

Please remember:

The information provided here is for general knowledge and educational purposes only.
It is not intended to be a substitute for professional financial advice.
Every individual's financial situation is unique, and what works for one person may not work for another.
Before making any investment or financial decisions, you should always consult with a qualified financial advisor who understands your specific circumstances and goals.

Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, should never be acted upon. Please be aware that any information posted on this site should not be considered to be financial advice and i am not a financial advisor.